Immunic Exercises its Worldwide Exclusive Option to License for IMU-856 with Daiichi Sankyo

 Immunic Exercises its Worldwide Exclusive Option to License for IMU-856 with Daiichi Sankyo

Shots:

  • Immunic has exercised its exclusive option to license a group of compounds for Daiichi’s IMU-856. Daiichi to receive up front, certain future development, approval & sales milestone payments plus royalties on IMU-856. Immunic to get exclusive commercialization rights for IMU-856 in all countries, including the US, EU, and Japan
  • Additionally, the option includes patent exclusivity filled by Daiichi for IMU-856’s composition of matter. In Nov, 2018 Daiichi signed an exclusive WW option and license agreement with Immunic for IMU-856
  • IMU-856 is an orally administered modulator that restores the intestinal barrier function developed originally by Daiichi and will be evaluated in P-I for patients suffering from gastrointestinal diseases in H1’20

Click here to read full press release/ article | Ref: Immunic | Image: Behance

Shiwani Sharma

Shiwani Sharma is a Senior Editor at PharmaShots. She has in-depth knowledge of lifesciences industry including pharma and biotech sectors. She also covers news in field of Digital Health, Medtech and regulatory approvals from the US FDA, EU, and other global regulatory bodies in the industry. Additionally, she also writes Whitepapers, analysis reports, blogs on pharma and biotech industry. She is graduate in Biotechnology. She can be contacted on shiwani@pharmashots.com

Related post